Clinical transplantation · 2025
Belatacept-Based Immunosuppression and Donor-Specific Antibodies in Lung Transplant: A Multi-Institutional Retrospective Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Younis Moustafa, Mederos Christopher I, Miller Cecelia M, Kumar Pooja, Ishaq Ariana, Mu Amy, Gries Cynthia, Reams Victoria, Aladaileh Mohammad A, Rackauskas Mindaugas, Kaza Vaidehi, Bollineni Srinivas, Torres Fernando, Emtiazjoo Amir, Timofte Irina
Аннотация
BACKGROUND: Belatacept use in renal transplant is associated with similar graft survival and elimination of preexisting donor-specific antibodies (DSA). We aim to describe the impact of Belatacept use on de novo DSA in lung transplant (LTx).
METHODS: A multi-institutional retrospective review of LTx patients with de novo DSA who received Belatacept (January 2018-August 2023) was performed. The primary outcome is the change in DSA post Belatacept initiation. Changes in mean fluorescence intensity (MFI) before and after Belatacept administration were analyzed using a linear mixed-effects model. Secondary outcomes included antibody-mediated rejection (AMR).
RESULTS: Forty-four patients with DSA received Belatacept. Most DSA were class II (n = 41, 93%), with a median (IQR) MFI of 4000 (2500-7000) at Belatacept initiation. Following Belatacept initiation, DSA resolved in (n = 25, 57%) patients, decreased in (n = 7, 16%), and remained unchanged in (n = 12, 27%). No de novo DSA developed during Belatacept therapy. There was no significant change in MFI pre Belatacept administration (change = -38, 95% CI: -267 to 191, p = 0.745), whereas MFI decreased significantly post Belatacept administration (change = -334, 95% CI: -449 to -219, p < 0.001). A total of (n = 25, 57%) patients experienced AMR prior to initiating Belatacept. None of the patients developed AMR while on Belatacept.
CONCLUSION: This is the largest cohort to date of LTx patients with DSA who received Belatacept. Belatacept use was associated with a reduction in DSA.
METHODS: A multi-institutional retrospective review of LTx patients with de novo DSA who received Belatacept (January 2018-August 2023) was performed. The primary outcome is the change in DSA post Belatacept initiation. Changes in mean fluorescence intensity (MFI) before and after Belatacept administration were analyzed using a linear mixed-effects model. Secondary outcomes included antibody-mediated rejection (AMR).
RESULTS: Forty-four patients with DSA received Belatacept. Most DSA were class II (n = 41, 93%), with a median (IQR) MFI of 4000 (2500-7000) at Belatacept initiation. Following Belatacept initiation, DSA resolved in (n = 25, 57%) patients, decreased in (n = 7, 16%), and remained unchanged in (n = 12, 27%). No de novo DSA developed during Belatacept therapy. There was no significant change in MFI pre Belatacept administration (change = -38, 95% CI: -267 to 191, p = 0.745), whereas MFI decreased significantly post Belatacept administration (change = -334, 95% CI: -449 to -219, p < 0.001). A total of (n = 25, 57%) patients experienced AMR prior to initiating Belatacept. None of the patients developed AMR while on Belatacept.
CONCLUSION: This is the largest cohort to date of LTx patients with DSA who received Belatacept. Belatacept use was associated with a reduction in DSA.